medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2002, Number 3

<< Back Next >>

Ann Hepatol 2002; 1 (3)

Hepatitis C and liver transplantation

Moreno R, Berenguer M

Language: English
References: 49
Page: 129-135
PDF size: 63.36 Kb.


Text Extraction

Hepatitis C virus-related end-stage liver disease, alone or in combination with alcohol, has become the leading indication for liver transplantation in most transplant programs accounting for approximately half of transplants performed in European centers. The aim of this review is to analyze the factors involved in the results in different groups of patients with HCV underwent to liver transplantation. The groups involved those pretransplantation, post-transplant HCV infection, preventive early post-transplantation and with of recurrent hepatitis C.


REFERENCES

  1. European Liver Transplant Registry: www.eltr.org

  2. Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Sem Liv Dis 2000; 20: 1-16.

  3. Fattovitch G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463-72.

  4. Shiratori Y, Shiina S, Teratani T, et al. Combination of tumor ablation and interferon therapy remarkably improves prognosis and liver function in hepatitis C viral-hepatocellular carcinoma. Hepatology 2000; 32: 206A.

  5. Pereira BJ, Wright TL, Schmid CH, Levey AS. A controlled study of hepatitis C transmission by organ transplantation. Lancet 1995; 345: 484-7.

  6. Testa G, Goldstein RM, Netto G, et al. Long-term outcome of patients transplanted with livers from hepatitis C-positive donors. Transplantation 1998; 65: 925-9.

  7. Vargas HE, Laskus T, Wang LF, et al. Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts. Gastroenterology 1999; 117: 149-53.

  8. Wright TL, Donegan E, Hsu H et al. Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology 1992; 103: 317-22.

  9. Chazouilleres O, Kim M, Combs C et al. Quantitation of Hepatitis C Virus RNA in Liver Transplant Recipients. Gastroenterology 1994; 106: 994-9.

  10. Pelletier SJ, Raymond DP, Crabtree TD, et al. Hepatitis C-induced hepatic allograft injury is associated with a pre-transplantation elevated viral replication rate. Hepatology 2000; 32: 418-426.

  11. Prieto M, Berenguer M, Rimola A, et al. Liver Transplantation in hepatitis C: a Spanish multicenter experience. Eur J Gastroenterol Hepatol 1998; 10: 771-776

  12. Gane E, Portmann B, Naoumov N, et al. Long-Term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334:815-820.

  13. Prieto M, Berenguer M, Rayón M, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999; 29:250-256 .

  14. Feray C, Caccamo L, Alexander GJM, et al. European Collaborative Study on factors influencing the outcome after liver transplantation for hepatitis C. Gastroenterology 1999; 117: 619-25.

  15. Testa G, Crippin JS, Netto GJ, et al. Liver transplantation for hepatitis C: recurrence and disease progression in 300 patients. Liver Transpl 2000; 6: 553-561.

  16. Sanchez-Fueyos A, Restrepo J-C, Quintó Llorenc, et al. Impact of the recurrence of hepatitis C infection after liver transplantation on the long term viability of the graft. Transplantation 2002; 73: 56-63.

  17. Berenguer M, Ferrell L, Watson J, et al. HCV-related fibrosis progression following liver transplantation: increase in recent years. J Hepatol 2000; 32: 673-684.

  18. Berenguer M, Rayón M, Prieto M, et al. Are post-transplantation protocol liver biopsies useful in the long-term? Liver transplantation 2001;7: 790-6.

  19. Berenguer M, Prieto M, San Juan F, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002; 36: 202-210.

  20. Berenguer M, Prieto M, Rayón JM, et al. Natural history of clinically compensated HCV-related graft cirrhosis following liver transplantation. Hepatology 2000; 32: 852-8.

  21. Forman LM, Lewis JD, Berlin JA, et al. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896.

  22. Berenguer M, Lopez-Labrador FX, Wright TL. Hepatitis C and Liver transplantation. J Hepatol 2001; 35: 666-678.

  23. Gigou M, Roque-Alfonso AM, Falissard B, et al. Genetic clustering of hepatitis C virus strains and severity of recurrent hepatitis after liver transplantation. J Virol 2001; 75: 11292-7.

  24. Schluger L, Sheiner P, Thung S, et al. Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology 1996; 23: 971-976.

  25. DiMartino V, Saurini F, Samuel D, et al. Long-term longitudinal study of intrahepatic hepatitis C virus replication after liver transplantation. Hepatology 1997; 26: 1343-1350.

  26. Charlton M, Seaberg E, Wiesner R, et al. Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology 1998; 28: 823-30

  27. Sreekumar R, Gonzalez-Koch A, Maor-Kendler Y, et al. Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology 2000; 32: 1125-30.

  28. Rosen HR, Hinrichs DJ, Gretch DR, et al. Association of multispecific CD4+ response to hepatitis C and severity of recurrence after liver transplantation. Gastroenterology 1999; 117: 926-32.

  29. Jain A, Kashyap R, Demetris AJ, Eghstesad B, Pokharna R, Fung JJ. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C. Liver Transpl 2002; 8(1): 40-6.

  30. Nelson DR, Soldevila-Pico C, Reed A, et al. The effect of anti-interleukin-2 receptor therapy on the course of hepatitis C recurrence after liver transplantation. Liver Transpl 2001; 7: 1064-1070.

  31. Brillanti S, et al. Slowly tapering off steroids protects the graft against hepatitis C recurrence after liver transplantation. Liver Transpl (in press).

  32. Crippin JS, Sheiner P, Terrault NA, et al. A pilot study of the tolerability and efficacy of antiviral therapy in patients awaiting liver transplantation for hepatitis C. Liver Transplantation 2002; 8: 350-355.

  33. Everson GT, Trouillot T, Trotter J, et al. Treatment of decompensated cirrhotics with a slow-accelearting dose regimen (LADR) of interferon-alfa-2b plus ribavirin: safety and efficacy. Hepatology 2000; 32: 308A.

  34. Sheiner P, Boros P, Klion FM, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998; 28: 831-38.

  35. Singh N, Gayowski T, Wannstedt C, et al. Interferon-a for prophylaxis of recurrent viral hepatitis C in liver transplant recipients. Transplantation 1998; 65: 82-86.

  36. Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transpl Proc 2001; 33: 1355-1357.

  37. Wright TL, Combs C, Kim M, et al. Interferon alpha therapy for hepatitis C virus infection following liver transplantation. Hepatology 1994; 20: 773-9.

  38. Feray C, Samuel D, Gigou M, et al. An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: antiviral effects and risk of rejection. Hepatology 1995; 22: 1084-1089.

  39. Gane EJ, Lo SK, Riordan SM, et al. A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation. Hepatology 1998; 27: 1403-07.

  40. Bizollon T, Palazzo U, Ducerf C, et al. Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology 1997: 26: 500-504.

  41. Alberti AB, Belli LS, Airoldi A, et al. Combined therapy with interferon and low-dose ribavirin in post-transplantation recurrent hepatitis C: a pragmatic study. Liver Transpl 2001; 7(10): 870-6.

  42. Gopal DV, Rabkin JM, Berk BS, et al. Treatment of progressive hepatitis C recurrence after liver transplantation with combination interferon plus ribavirin. Liver Transpl 2001; 7(3): 181-90.

  43. Ahmad J, Dodson SF, Demetris AJ, Fung JJ, Shakil AO. Recurrent hepatitis C after liver transplantation: a non randomized trial of interferon alfa alone versus interferon alfa and ribavirin. Liver Transpl 2001; 7(10): 863-9.

  44. De Vera ME, Smallwood GA, Rosado K, et al. Interferon-alpha and ribavirin for the treatment of recurrent hepatitis Cafter liver transplantation. Transplantation 2001; 71(5): 678-86.

  45. Narayanan M, Poterucha JJ, El-Amin OM, et al. Treatment of post-transplantation recurrence of hepatitis C wih interferon and ribavirin: lessons on tolerability and efficacy. Liver Transpl 2002; 8: 623-9.

  46. Bizollon T, Ducerf C, Chevallier M, et al. Long-term efficacy of ribavirin plus IFN in the treatment of HCV recurrence after liver transplantation. 11th Congress of the European Society for Organ Transplantation. Oslo 1999, June 19-24 (Abst 20).

  47. Sheiner PA, Schluger LK, Emre S, et al. Retransplantation for recurrent hepatitis C. Liver Transpl Surg 1997; 3: 130-6.

  48. Rosen H, O’Reilly P, Shackleton C, et al. Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation 1997; 62: 1773-1776.

  49. Rosen HR, Madden JP, Martin P. A model to predict survival following liver retransplantation. Hepatology 1999; 29: 365-70.




2020     |     www.medigraphic.com